Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
- PMID: 33816271
- PMCID: PMC8018233
- DOI: 10.3389/fonc.2021.632657
Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
Keywords: MDR; P-gp overexpresssion; anticancer drug; cancer stem cell; drug repositioning; lower toxicity; molecular targeting; resistant cancer.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
